Alterations of calcium metabolism and of parathyroid function in primary aldosteronism, and their reversal by spironolactone or by surgical removal of aldosterone-producing adenomas.
In order to investigate the possible existence of abnormal calcium metabolism and parathyroid function in primary aldosteronism (PA), we have compared the calcium/parathyroid hormone (PTH) profile of patients with PA with the profile of healthy normotensive subjects and of patients with essential hypertension (EH). Furthermore, we have evaluated the effects of spironolactone and the surgical removal of aldosterone-producing adenomas on the calcium/PTH profile in the PA patients. Four groups of 10 subjects each participated in the study: 1) hypertensive patients with PA, 2) patients with low-renin EH (LREH), 3) patients with normal-renin EH (NREH), 4) normotensive healthy subjects (NS). The four groups were well-matched for age, sex, body mass index, and renal function. The three hypertensive groups were also matched closely for blood pressure values and for duration of hypertension. In all subjects, after 1 week of a controlled intake of Na and K, the following parameters were measured: urine excretion of Na, K, Ca, Mg, and P, plasma levels of K, Mg, inorganic P, total calcium and ionized calcium, and plasma renin activity, aldosterone concentration, and intact PTH. Blood pressure and laboratory parameters were determined again in all the PA patients after 1 month of 100 mg daily spironolactone administration, and in four out of the 10 PA patients 2 months after surgical removal of aldosterone-producing adenomas. All of these subjects had undergone the same controlled intake of Na and K indicated above. Serum intact PTH was higher in PA patients than in the other three groups (P < .01), and serum ionized calcium was significantly higher in normotensive subjects than in the three hypertensive groups (v PA P < .01, v LREH and v NREH P < .05). An increase in serum ionized calcium and a decrease in PTH level were associated with both spironolactone administration (P < .001) and surgical treatment (P < .05). These results suggest the presence of calcium metabolism alterations in both PA and EH patients, but that these alterations are more exaggerated in PA, so that higher PTH levels are needed for maintaining low-normal levels of serum ionized calcium.
Rossi
E
E
Fourth Department of Internal Medicine, S. Maria Nuova Hospital, Reggio Emilia, Italy.
Sani
C
C
Perazzoli
F
F
Casoli
M C
MC
Negro
A
A
Dotti
C
C
D000306:Adrenal Cortex Neoplasms / Q000150:complications / Q000378:metabolism* / Q000628:therapy; D000315:Adrenalectomy; D018246:Adrenocortical Adenoma / Q000150:complications / Q000378:metabolism* / Q000628:therapy; D000328:Adult; D000368:Aged; D000450:Aldosterone / Q000378:metabolism; D000704:Analysis of Variance; D001794:Blood Pressure; D015992:Body Mass Index; D002118:Calcium / Q000378:metabolism*; D003404:Creatinine / Q000378:metabolism; D005260:Female; D006801:Humans; D006929:Hyperaldosteronism / Q000209:etiology / Q000378:metabolism* / Q000628:therapy; D006973:Hypertension / Q000150:complications / Q000378:metabolism / Q000628:therapy; D008297:Male; D008875:Middle Aged; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use*; D010280:Parathyroid Glands / Q000187:drug effects / Q000378:metabolism*; D010281:Parathyroid Hormone / Q000378:metabolism; D013148:Spironolactone / Q000627:therapeutic use*
D000451:Mineralocorticoid Receptor Antagonists; D010281:Parathyroid Hormone; D013148:Spironolactone; D000450:Aldosterone; D003404:Creatinine; D002118:Calcium